-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
November 2019
-
IASLC’s Inaugural Mesothelioma Meeting Sets Baseline for Strategic Approach to Patient Care
Posted: November 15, 2019 As a rare orphan disease, mesothelioma research has been slowed by a lack of eligible patients for trials and by a dearth of resources. Because of these hurdles, agreement among oncologists and researchers in the field regarding strategic priorities is necessary. The IASLC 2018 Mesothelioma Meeting held this past July in…
-
Key Findings from the CAR T-Cell Study Presented at the 2019 AACR Annual Meeting
By Prasad S. Adusumilli, MD, FACS, FCCP Posted: November 12, 2019 My colleagues and I conducted a phase I clinical trial of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with malignant pleural disease from mesothelioma and metastatic lung or breast cancer, and we presented the findings at the 2019 American Association for Cancer…
-
Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?
By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 Dr. Si-Yang Liu Dr. Yi-Long Wu In the twentieth century, adjuvant chemotherapy became the standard of care for resected NSCLC based on several clinical trials including IALT, JBR.10, ANITA, and a meta-analysis of individual patient data from the LACE trial. Adjuvant chemotherapy increased…
-
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive biomarker for patients with advanced NSCLC and is routinely performed to determine eligibility for pembrolizumab therapy, either as monotherapy or in combination with chemotherapy or,…
-
Changing E-Cigarette Technology Leads to Increased Complexity and Confusion—IASLC Statement Aims for Clarity
Posted: November 12, 2019 Dr. Matthew Steliga, chair of the IASLC Tobacco Control and Smoking Cessation Committee and thoracic surgeon and head of the Tobacco Cessation Program at Winthrop P. Rockefeller Cancer Institute, met with IASLC Lung Cancer News (ILCN) to discuss the impetus for the statement, the role of electronic cigarettes in tobacco cessation,…
-
Antibody–Drug Conjugates in NSCLC: Complexities, Challenges, and Potential
By David E. Gerber, MD Posted: November 12, 2019 Dr. David E. Gerber The underlying concept for antibody–drug conjugates (ADCs) is relatively straightforward: capitalize on the highly specific targeting of monoclonal antibodies to convey a lethal payload to cancer cells while minimizing exposure of normal tissues. However, after more than 20 years of clinical development,…
-
Luis E. Raez, MD
Posted: November 12, 2019 Luis E. Raez, MD, has been elected 2019-2021 President of the Florida Society of Clinical Oncology (FLASCO). With more than 3,500 members, FLASCO plays a very important role in relationships with industry, payors, and education for oncology providers and advocacy for their patients. Dr. Raez hopes to increase rates of lung…
-
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of thoracic oncology patient care, the conference offered attendees from all specialties an opportunity to learn about novel research and hear from the field’s top experts.…